.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202236

« Back to Dashboard
NDA 202236 describes DYMISTA, which is a drug marketed by Meda Pharms and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug and one Paragraph IV challenge. Additional details are available on the DYMISTA profile page.

The generic ingredient in DYMISTA is azelastine hydrochloride; fluticasone propionate. There are twelve drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the azelastine hydrochloride; fluticasone propionate profile page.

Summary for NDA: 202236

Tradename:
DYMISTA
Applicant:
Meda Pharms
Ingredient:
azelastine hydrochloride; fluticasone propionate
Patents:3
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 202236

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DYMISTA
azelastine hydrochloride; fluticasone propionate
SPRAY, METERED;NASAL 202236 NDA Meda Pharmaceuticals Inc. 0037-0245 0037-0245-06 1 BOTTLE, SPRAY in 1 BOX (0037-0245-06) > 28 SPRAY, METERED in 1 BOTTLE, SPRAY
DYMISTA
azelastine hydrochloride; fluticasone propionate
SPRAY, METERED;NASAL 202236 NDA Meda Pharmaceuticals Inc. 0037-0245 0037-0245-23 1 BOTTLE, SPRAY in 1 BOX (0037-0245-23) > 120 SPRAY, METERED in 1 BOTTLE, SPRAY

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SPRAY, METERED;NASALStrengthEQ 0.125MG BASE/SPRAY;0.05MG/SPRAY
Approval Date:May 1, 2012TE:RLD:Yes
Patent:8,163,723*PEDPatent Expiration:Feb 29, 2024Product Flag?Substance Flag?Delist Request?Y
Patent:8,168,620*PEDPatent Expiration:Aug 24, 2026Product Flag?Substance Flag?Delist Request?Y
Patent:9,259,428*PEDPatent Expiration:Dec 13, 2023Product Flag?Substance Flag?Delist Request?Y


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc